Bloomberg -- A daily pill helped protect gay and bisexual men from HIV for the first time in a landmark study. Gilead Sciences Inc.’s Truvada, sold to subdue the AIDS- causing virus in those already infected, cut the risk of contracting HIV by 44 percent, according to findings published today in the New England Journal of Medicine. The drug reduced new infections as much as 73 percent in those who used it most.
